Clean Sweep Live Auction on Thur. March 28th. Click to view the full inventory

DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
Current Location:
> This Story

Log in or Register to rate this News Story
Forward Printable StoryPrint Comment




Rad Oncology Homepage

Four considerations before embarking on a carbon therapy center The next frontier in improving cancer care

Q&A with Scott Warwick, executive director of the National Association for Proton Therapy Find out what to expect at the year's biggest proton therapy industry event

New approach identifies lung cancer patients most likely to respond to chemotherapy Combines radiomics and CT image assessment

Aussies and Americans develop 3D models for assessing impacts of radiotherapy Test different levels and types of radiation

Law in Ontario prevents cremation of brachytherapy patients Experts call for eliminating the law, as it deters patients from lifesaving treatment

IBA tech plays first-time role in flash therapy demonstration Supports eventual integration of flash as clinical treatment

Access to proton therapy increasing for pediatric patients Young cancer patients have the most to gain from proton treatment

Public-private partnership replaces 50-year old radiotherapy equipment in Guatemala Upgrading to Varian Halcyon system

Hypofractionated radiotherapy no worse than conventional RT, says study No difference in progression and survival

Proton therapy market continues decline after 2015 high point: report By comparison, investment in 2018 dropped 62 percent

ViewRay showcases developing
enhancements for MRIdian Linac
radiotherapy system at ESTRO

ViewRay showcases enhancements to MRIdian Linac system at ESTRO

by John R. Fischer , Staff Reporter
MR pulse sequencing is one in a series of enhancements that ViewRay Inc. showcased this weekend in its MRIdian’s SmartVision MR image guidance technology at ESTRO 2018 in Barcelona, Spain.

The Ohio-based enterprise plans to develop the upgrades to heighten the bone and soft tumor visualization capabilities of its MRIdian Linac radiotherapy system to ensure greater precision in radiation delivery. News of the enhancements follows the recent implementation of the solution earlier this month at the University Clinic Heidelberg in Germany.

Story Continues Below Advertisement

RaySafe helps you avoid unnecessary radiation

RaySafe solutions are designed to minimize the need for user interaction, bringing unprecedented simplicity & usability to the X-ray room. We're committed to establishing a radiation safety culture wherever technicians & medical staff encounter radiation.

"We are grateful to the German Research Foundation (DFG) for granting us the opportunity to utilize such a cutting-edge instrument to investigate the benefits of soft-tissue visualization and real-time plan adaptation to improve our patient treatment,” medical director and professor Jürgen Debus, head of the MRIdian Linac program and the Heidelberg Heavy Ion Center, said in a statement upon the completion of the installation.

The solution will utilize T1w and T2w MR pulse sequences for the development of visuals, as well as enhanced contrast between malignant and healthy tissue.

Further assistance will potentially be available with the integration of diffusion-weighted imaging for distinguishing between tumors and normal tissue; and for the possible assessment and prediction of tumor response to radiotherapy.

The integration of these enhancements is set to double the speed of MRIdian’s SmartVISION’s MR imaging from four to eight frames per second. The technology will also provide two times higher image resolution and double improvement in MR signal-to-noise ratio (SNR), producing brighter and more detailed anatomical imaging.

In addition, the University Clinic Heidelberg will research the system's potential for enhancing dose delivery through MR-guidance. Another partner, the University Hospital Zurich, will investigate response prediction and assessment.

The enhancements are under development and only available for sale in the European Economic Area.

The first generation of the solution is FDA cleared and can be purchased by U.S. consumers.

ViewRay Inc. did not respond for comment.

Rad Oncology Homepage

You Must Be Logged In To Post A Comment

Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Gold Service Dealer Program
Receive RFP/PS
Healthcare Providers
See all
HCP Tools
A Job
Parts Hunter +EasyPay
Get Parts
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2019 DOTmed.com, Inc.